Formulating Spray-Dried Albumin-Modified Lipid Nanoparticles Encapsulating Acyclovir for Enhanced Pulmonary Drug Delivery
Frontiers in Bioscience-Landmark · 2024
DOI: 10.31083/j.fbl2910363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Kewei Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular and Endovascular Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of …. Hauptthemen laut MEDLINE: Acyclovir, Nanoparticles, Antiviral Agents, Lipids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Pudong New Area Health Committee Project, Project of Key Medical Discipline Group Construction in Shanghai Pudong New Area, Project of Clinical Outstanding Discipline Construction in Shanghai Pudong New Area.
Abstract (Originalsprache)
Background
Viral pneumonia, a pressing global health issue, necessitates innovative therapeutic approaches. Acyclovir, a potent ring-opening antiviral agent with broad-spectrum activity, faces water solubility, oral bioavailability, and drug resistance challenges. The aim of this study was to increase the efficacy of acyclovir through respiratory delivery by encapsulating it within albumin-modified lipid nanoparticles and formulate it as a spray.
Methods
Nanoparticles was synthesized via the reverse evaporation method; its physicochemical characteristics were rigorously evaluated, including particle size, zeta potential, morphology, encapsulation efficiency, drug loading, and release profile. Furthermore, the cytotoxicity of nanoparticles and its therapeutic potential against viral pneumonia were assessed through cellular and animal model experiments. Result s: Nanoparticles exhibited a spherical morphology, with a mean particle size of 97.48 ± 5.36 nm and a zeta potential of 30.28 ± 4.72 mv; they demonstrated high encapsulation efficiency (93.26 ± 3.27%), drug loading (11.36 ± 0.48%), and a sustained release profile of up to 92% under neutral conditions. Notably, nanoparticles showed low cytotoxicity and efficient intracellular delivery of acyclovir. In vitro studies revealed that nanoparticles significantly reduced interleukin-6 levels induced by influenza virus stimulation. In vivo, nanoparticles treatment markedly decreased mortality, attenuated the inflammatory markers interleukin-6 and tumor necrosis factor-α levels, and mitigated inflammatory lung injury in mice with viral pneumonia.
Conclusions
In this study, albumin was modified with polyethylene glycol (PEG) containing cationic lipid nanoparticles (LN) to prepare albumin-modified lipid nanoparticles encapsulating acyclovir (ALN-Acy), which can effectively deliver Acy into tissues and cells, prolong the survival of mice, and reduce lung injury and inflammatory factors. White albumin LN can be used as efficient drug delivery carriers, and the delivery of Acy via albumin LN is expected to be a therapeutic strategy for treating inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Vascular and Endovascular Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, 450003 Zhengzhou, Henan, China.
- Emergency and Critical Care Medicine, Shanghai Pudong New Area People's Hospital, 201299 Shanghai, China.
- Institute of Translational Medicine, Shanghai University, 200444 Shanghai, China.
Förderung
- Shanghai Pudong New Area Health Committee Project
- Project of Key Medical Discipline Group Construction in Shanghai Pudong New Area
- Project of Clinical Outstanding Discipline Construction in Shanghai Pudong New Area
Zitieren
APA
Zhang, K., Han, Z., Chen, D., Zhang, C., Zhang, Q., Cai, B., Qin, Y., Wang, K., Shang, F., & Wan, J. (2024). Formulating Spray-Dried Albumin-Modified Lipid Nanoparticles Encapsulating Acyclovir for Enhanced Pulmonary Drug Delivery. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2910363
Vancouver
Zhang K, Han Z, Chen D, Zhang C, Zhang Q, Cai B, et al. Formulating Spray-Dried Albumin-Modified Lipid Nanoparticles Encapsulating Acyclovir for Enhanced Pulmonary Drug Delivery. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2910363
BibTeX
@article{Zhang2024,
author = {Zhang, Kewei and Han, Zhen and Chen, Dagui and Zhang, Chenxi and Zhang, Qian and Cai, Bo and Qin, Yafei and Wang, Kai and Shang, Fusheng and Wan, Jian},
title = {Formulating Spray-Dried Albumin-Modified Lipid Nanoparticles Encapsulating Acyclovir for Enhanced Pulmonary Drug Delivery},
journal = {Frontiers in Bioscience-Landmark},
year = {2024},
doi = {10.31083/j.fbl2910363}
}
EUVIMED